-
Je něco špatně v tomto záznamu ?
P2Y12 Inhibitor Loading Time Before Elective PCI and the Prevention of Myocardial Necrosis
V. Roule, F. Beygui, G. Cayla, G. Rangé, Z. Motovska, N. Delarche, F. Jourda, P. Goube, P. Guedeney, M. Zeitouni, M. El Kasty, M. Laredo, R. Dumaine, G. Ducrocq, F. Derimay, E. Van Belle, T. Manigold, R. Cador, N. Combaret, E. Vicaut, G....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antagonisté purinergních receptorů P2Y terapeutické užití MeSH
- infarkt myokardu * etiologie MeSH
- inhibitory agregace trombocytů terapeutické užití MeSH
- klopidogrel terapeutické užití MeSH
- koronární angioplastika * metody MeSH
- lidé MeSH
- ticagrelor terapeutické užití MeSH
- výsledek terapie MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
BACKGROUND: There are dated and conflicting data about the optimal timing of initiation of P2Y12 inhibitors in elective percutaneous coronary intervention (PCI). Peri-PCI myocardial necrosis is associated with poor outcomes. We aimed to assess the impact of the P2Y12 inhibitor loading time on periprocedural myocardial necrosis in the population of the randomized Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting (ALPHEUS) trial, which compared ticagrelor with clopidogrel in high-risk patients who received elective PCI. METHODS: The ALPHEUS trial divided 1809 patients into quartiles of loading time. The ALPHEUS primary outcome was used (type 4 [a or b] myocardial infarction or major myocardial injury) as well as the main secondary outcome (type 4 [a or b] myocardial infarction or any type of myocardial injury). RESULTS: Patients in the first quartile group (Q1) presented higher rates of the primary outcome (P = 0.01). When compared with Q1, incidences of the primary outcome decreased in patients with longer loading times (adjusted odds ratio [adjOR], 0.70 [0.52.-0.95]; P = 0.02 for Q2; adjOR 0.65 [0.48-0.88]; P < 0.01 for Q3; adjOR 0.66 [0.49-0.89]; P < 0.01 for Q4). Concordant results were found for the main secondary outcome. There was no interaction with the study drug allocated by randomization (clopidogrel or ticagrelor). Bleeding complications (any bleeding ranging between 4.9% and 7.3% and only 1 major bleeding at 48 hours) and clinical ischemic events were rare and did not differ among groups. CONCLUSIONS: In elective PCI, administration of the oral P2Y12 inhibitor at the time of PCI could be associated with more frequent periprocedural myocardial necrosis than an earlier administration. The long-term clinical consequences remain unknown.
ACTION Study Group Sorbonne Université INSERM UMRS1166 Hôpital Pitié Salpêtrière Paris France
Cardiology Department CHU Nantes Nantes France
Département de Cardiologie CH de Chartres Chartres France
Département de Cardiologie CH François Mitterrand Pau France
Département de Cardiologie CHU de Caen Caen France
Department of Cardiology Grand Hôpital de l'Est Francilien Jossigny France
Department of Cardiology Saint Joseph Hospital Paris France
Les Grands Prés Cardiac Rehabilitation Centre Villeneuve St Denis France
Service de Cardiologie Centre Hospitalier Sud Francilien Corbeil Essonnes France
Service de Cardiologie CH Auxerre Auxerre France
Service de Cardiologie Interventionnelle Hospices Civils de Lyon and CARMEN INSERM 1060 Lyon France
Université de Paris AP HP French Alliance for Cardiovascular Trials INSERM U1148 Paris France
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24007837
- 003
- CZ-PrNML
- 005
- 20240423160321.0
- 007
- ta
- 008
- 240412s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1016/j.cjca.2023.08.028 $2 doi
- 035 __
- $a (PubMed)37660934
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Roule, Vincent $u ACTION Study Group, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France; Département de Cardiologie, CHU de Caen, Caen, France
- 245 10
- $a P2Y12 Inhibitor Loading Time Before Elective PCI and the Prevention of Myocardial Necrosis / $c V. Roule, F. Beygui, G. Cayla, G. Rangé, Z. Motovska, N. Delarche, F. Jourda, P. Goube, P. Guedeney, M. Zeitouni, M. El Kasty, M. Laredo, R. Dumaine, G. Ducrocq, F. Derimay, E. Van Belle, T. Manigold, R. Cador, N. Combaret, E. Vicaut, G. Montalescot, J. Silvain, ALPHEUS Investigators
- 520 9_
- $a BACKGROUND: There are dated and conflicting data about the optimal timing of initiation of P2Y12 inhibitors in elective percutaneous coronary intervention (PCI). Peri-PCI myocardial necrosis is associated with poor outcomes. We aimed to assess the impact of the P2Y12 inhibitor loading time on periprocedural myocardial necrosis in the population of the randomized Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting (ALPHEUS) trial, which compared ticagrelor with clopidogrel in high-risk patients who received elective PCI. METHODS: The ALPHEUS trial divided 1809 patients into quartiles of loading time. The ALPHEUS primary outcome was used (type 4 [a or b] myocardial infarction or major myocardial injury) as well as the main secondary outcome (type 4 [a or b] myocardial infarction or any type of myocardial injury). RESULTS: Patients in the first quartile group (Q1) presented higher rates of the primary outcome (P = 0.01). When compared with Q1, incidences of the primary outcome decreased in patients with longer loading times (adjusted odds ratio [adjOR], 0.70 [0.52.-0.95]; P = 0.02 for Q2; adjOR 0.65 [0.48-0.88]; P < 0.01 for Q3; adjOR 0.66 [0.49-0.89]; P < 0.01 for Q4). Concordant results were found for the main secondary outcome. There was no interaction with the study drug allocated by randomization (clopidogrel or ticagrelor). Bleeding complications (any bleeding ranging between 4.9% and 7.3% and only 1 major bleeding at 48 hours) and clinical ischemic events were rare and did not differ among groups. CONCLUSIONS: In elective PCI, administration of the oral P2Y12 inhibitor at the time of PCI could be associated with more frequent periprocedural myocardial necrosis than an earlier administration. The long-term clinical consequences remain unknown.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a klopidogrel $x terapeutické užití $7 D000077144
- 650 _2
- $a ticagrelor $x terapeutické užití $7 D000077486
- 650 _2
- $a antagonisté purinergních receptorů P2Y $x terapeutické užití $7 D058921
- 650 12
- $a koronární angioplastika $x metody $7 D062645
- 650 12
- $a infarkt myokardu $x etiologie $7 D009203
- 650 _2
- $a inhibitory agregace trombocytů $x terapeutické užití $7 D010975
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Beygui, Farzin $u Département de Cardiologie, CHU de Caen, Caen, France
- 700 1_
- $a Cayla, Guillaume $u Cardiology Department, Nîmes University Hospital, Montpellier University, ACTION Study Group, Nîmes, France
- 700 1_
- $a Rangé, Grégoire $u Département de Cardiologie, CH de Chartres, Chartres, France
- 700 1_
- $a Motovska, Zuzana $u Cardiocentre, 3rd Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Prague, Czech Republic
- 700 1_
- $a Delarche, Nicolas $u Département de Cardiologie, CH François Mitterrand, Pau, France
- 700 1_
- $a Jourda, François $u Service de Cardiologie, CH Auxerre, Auxerre, France
- 700 1_
- $a Goube, Pascal $u Service de Cardiologie, Centre Hospitalier Sud-Francilien, Corbeil-Essonnes, France
- 700 1_
- $a Guedeney, Paul $u ACTION Study Group, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
- 700 1_
- $a Zeitouni, Michel $u ACTION Study Group, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
- 700 1_
- $a El Kasty, Mohamad $u Department of Cardiology, Grand Hôpital de l'Est Francilien, Jossigny, France
- 700 1_
- $a Laredo, Mikael $u ACTION Study Group, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
- 700 1_
- $a Dumaine, Raphaëlle $u Les Grands Prés Cardiac Rehabilitation Centre, Villeneuve St Denis, France
- 700 1_
- $a Ducrocq, Gregory $u Université de Paris, AP-HP, French Alliance for Cardiovascular Trials (FACT), INSERM U1148, Paris, France
- 700 1_
- $a Derimay, François $u Service de Cardiologie Interventionnelle, Hospices Civils de Lyon and CARMEN INSERM 1060, Lyon, France
- 700 1_
- $a Van Belle, Eric $u CHU Lille, Institut Cœur Poumon, Cardiology, and Department of Interventional Cardiology for Coronary, Valves and Structural Heart Diseases, INSERM U1011, Institut Pasteur de Lille, EGID, Université de Lille, Lille, France
- 700 1_
- $a Manigold, Thibaut $u Cardiology Department, CHU Nantes, Nantes, France
- 700 1_
- $a Cador, Romain $u Department of Cardiology Saint Joseph Hospital, Paris, France
- 700 1_
- $a Combaret, Nicolas $u Department of Cardiology, Clermont-Ferrand University Hospital, CNRS, Université Clermont Auvergne, Clermont-Ferrand, France
- 700 1_
- $a Vicaut, Eric $u Unité de Recherche Clinique, ACTION Study Group, Hôpital Fernand Widal (AP-HP), Paris, France and SAMM (Statistique, Analyse et Modélisation Multidisciplinaire) EA 4543, Université Paris 1 Panthéon, Sorbonne, France
- 700 1_
- $a Montalescot, Gilles $u ACTION Study Group, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France. Electronic address: http://www.action-cœur.org
- 700 1_
- $a Silvain, Johanne $u ACTION Study Group, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France
- 710 2_
- $a ALPHEUS Investigators
- 773 0_
- $w MED00001009 $t Canadian journal of cardiology $x 1916-7075 $g Roč. 40, č. 1 (2024), s. 31-39
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37660934 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240412 $b ABA008
- 991 __
- $a 20240423160317 $b ABA008
- 999 __
- $a ok $b bmc $g 2081690 $s 1217604
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 40 $c 1 $d 31-39 $e 20230903 $i 1916-7075 $m Canadian journal of cardiology $n Can J Cardiol $x MED00001009
- LZP __
- $a Pubmed-20240412
